RxDoctor Payments Data

Judith Rippert, DO

Cardiovascular Disease · Dover, DENPI 1871563114

Payments from drug & device makers

$750in general payments, 2019–2025

Across 44 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$179
  • Medtronic$143
  • Amgen$116
  • AstraZeneca$71
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$66
  • Gilead$55
  • plus $122 from 7 others

What the payments were for

  • Food & beverage$750100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$750 in reported general payments places this provider in the 25th percentile of 104 cardiovascular disease providers in Delaware.

See all cardiovascular disease providers in Delaware

Medicare billing

Part B allowed, 2024
$303,074
Medicare patients
1,500
Services billed
5,024

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban441$536,702
XareltoRivaroxaban170$196,195
MultaqDronedarone Hcl58$89,892
EntrestoSacubitril/Valsartan55$73,764
Repatha SureclickEvolocumab43$54,385
VascepaIcosapent Ethyl61$37,330
Rosuvastatin Calcium696$20,924
Atorvastatin Calcium758$15,290
BrilintaTicagrelor13$11,139
Praluent PenAlirocumab13$9,973
Metoprolol Succinate505$9,731
Ranolazine ErRanolazine67$9,359
Carvedilol632$8,684
Carvedilol ErCarvedilol Phosphate23$7,898
Ezetimibe183$7,716

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$536,702441 claims
Johnson & JohnsonXarelto$12$196,195170 claims
Sanofi-aventis U.S. LLCMultaq$28$89,89258 claims
NovartisEntresto$179$73,76455 claims
AstraZenecaBrilinta$71$11,13913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 104 cardiovascular disease providers in Delaware.

Other cardiovascular disease in Dover

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →